Liminatus Pharma Plans Phase 1 Trial of IBA101 CD47-Blocking Antibody for Lung Cancer
Key Insights
Liminatus Pharma (search) announced plans to initiate a Phase 1 clinical trial evaluating IBA101 (search), a next-generation CD47 (search)-blocking monoclonal antibody designed to enhance innate immune pathways.
The seamless clinical program will begin with monotherapy dose escalation followed by combination cohorts with PD-1 (search)/PD-L1 (search) checkpoint inhibitors within the same protocol.
Lung cancer has been selected as the initial focus, reflecting the widespread use of PD-1 (search)/PD-L1 (search) inhibitors and the need to improve response depth and durability.
Liminatus Pharma (search) announced plans to initiate a Phase 1 clinical trial evaluating IBA101 (search), a next-generation CD47 (search)-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies. The company is targeting readiness to advance the program following completion of required manufacturing, nonclinical, and regulatory preparation activities.
Mechanism of Action and Therapeutic Approach
IBA101 (search) is engineered to target the CD47 (search) "don't-eat-me" signal, a mechanism that enables tumor cells to evade innate immune surveillance. By enhancing macrophage-mediated tumor clearance and antigen presentation, IBA101 is designed to work alongside PD-1 (search)/PD-L1 (search) checkpoint inhibitors, which remain the backbone of treatment across multiple solid tumor indications.
The therapeutic approach addresses a critical gap in current immuno-oncology treatments by targeting the innate immune system, potentially complementing the adaptive immune responses activated by checkpoint inhibitors.
Clinical Trial Design and Strategy
The planned Phase 1 study is designed as a seamless clinical program, beginning with monotherapy dose escalation to evaluate safety, tolerability, and pharmacokinetics, followed by combination cohorts with PD-1 (search)/PD-L1 (search) therapies within the same protocol. This approach is intended to efficiently generate early clinical and translational insights while supporting disciplined dose selection for future development.
Lung cancer has been selected as the initial focus of the Phase 1 program, reflecting the widespread use of PD-1 (search)/PD-L1 (search) inhibitors in current treatment paradigms and the ongoing need to improve depth and durability of patient responses.
Clinical Leadership and Translational Research
The trial is planned to be conducted under the leadership of Dr. Se-Hoon Lee, a recognized expert in immuno-oncology clinical research. The study will incorporate translational analyses aimed at characterizing immune activity and identifying biological features associated with clinical benefit.
These translational components are designed to provide insights into the mechanism of action and help identify patient populations most likely to benefit from the therapy.
Regulatory and Development Timeline
The company anticipates engaging with regulatory authorities as part of its clinical development planning. Liminatus is currently completing required manufacturing, nonclinical, and regulatory preparation activities before advancing the program to clinical testing.